Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

A. R. Ibrahim; C. Paliompeis; M. Bua; D. Milojkovic; R. Szydlo; J. S. Khorashad; L. Foroni; A. Reid; H. de Lavallade; K. Rezvani; F. Dazzi; J. F. Apperley; J. M. Goldman; D. Marin

doi:10.1182/blood-2010-06-291922

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

By A. R. Ibrahim, C. Paliompeis, M. Bua, D. Milojkovic, R. Szydlo, J. S. Khorashad, L. Foroni, A. Reid, H. de Lavallade, K. Rezvani, F. Dazzi, J. F. Apperley, J. M. Goldman and D. Marin

Publisher: American Society of Hematology

Year: 2010

DOI identifier: 10.1182/blood-2010-06-291922

OAI identifier:

Provided by: MUCC (Crossref)

Download PDF:
_{Sorry, we are unable to provide the full text but you may find it at the
following location(s):}

http://www.bloodjournal.org/co... (external link)

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Suggested articles